Another remarkable protective mechanism of the human breast is the diathelic phenomenon. The diathelic mechanism is a wonder of nature. The breast is stimulated by bacteria introduced at the teat by the baby. The bacteria travel up the teat into the breast tissue, causing an immediate reaction with the formation of antibodies, which can then be found back in the mother's milk within eight hours. If the mother is healthy, this is a practically fool-proof system of protection for the baby. Klaus has stated it well, "The mother does not serve merely as a passive transmitter of immunity. Instead, the mammary gland is able to react to the microbes brought to it by the infant and respond with a fast production of specific antibody... The mammary gland is an exocrine reticuloendothelial gland which is 'lend leased' functionally to the infant at a time when his own reticuloendothelial system is inadequate."
Transfer factor is an immune system stimulant derived from white blood cells. Proponents claim transfer factor has anti germ activity. They also claim transfer factor may be beneficial in bronchial asthma and chronic fatigue syndrome.
I have not studied transfer factor in enough detail to have an opinion on it at this time. However, my initial reaction is that it would be difficult for a vitamin company to come up with a genuine transfer factor since it may be difficult to make this molecule in a laboratory. Therefore, for the time being, any vitamin company selling transfer factor needs to be looked at skeptically. If you would like to learn about supplements that have been studied for the immune system, visit the web page.
Folia Biol (Praha). 2013. Transfer factor: an overlooked potential for the prevention and treatment of infectious diseases. Transfer factor (TF) is a low-molecular-weight lymphocyte extract capable of transferring antigen-specific cell-mediated immunity (CMI) to T lymphocytes. It has been used successfully as an adjuvant or primary therapy for viral, parasitic, fungal, and some bacterial infections, as well as immunodeficiencies, neoplasias, allergies and autoimmune diseases. From the list of infections that seem to respond noticeably to transfer factor, those due to viruses of the herpes family are particularly remarkable. Indeed, for these viruses it was shown that TF can prevent infection or relapse, acting as a CMI vaccine. Data also suggest its possible use for adjuvant treatment and probably prevention of two currently widespread infections: tuberculosis and AIDS. Furthermore, TF has an interesting potential: answering the challenge from unknown pathogenic agents, a black box effect permitting production of antigen-specific TF to a new pathogen, even before its identification. It thus seems that the preventative potential of transfer factor is as important as its therapeutic one, both discussed in this review.
Transfer Factor Research
Transfer factor in the age of molecular biology: a review.
Current data suggests that the transferring of immunologically-specific information by transfer factor molecules requires interaction with a cell that has been genetically programmed to be antigen reactive but at the time of interaction is unprimed. Contact with transfer factor molecules would allow a naive recipient, on a first encounter with antigen, to make a secondary rather than a primary immunological response. Transfer factor molecules for each and every antigenic determinant are thus necessary. Transfer factors made from animals or humans are capable of transferring antigen specificity across a species barrier. Even primitive species have cells from which one can make transfer factors. The molecules are, therefore, well conserved and it is reasonable to suggest that they are important for normal immunological functioning. Proposed mechanisms of action must explain the fact that transfer factors obtained from the cells of high responder animals are capable of transferring delayed hypersensitivity to low responder animals while the reverse is not true. Transfer factor molecules are likely to interact with the variable regions of the alpha and/or beta chain of T cell receptors to change their avidity and affinity for antigen in a way that otherwise would only occur after an encounter with antigen.
The use of transfer factors in chronic fatigue syndrome: prospects and problems.
Biotherapy. 1996. Levine PH. Viral Epidemiology Branch, National Cancer Institute, Bethesda, MD, USA.
Chronic fatigue syndrome (CFS) is a heterogeneous disorder characterized by severe prolonged unexplained fatigue and a variety of associated symptoms such as arthralgias, myalgias, cognitive dysfunction, and severe sleep disturbances. Many patients initially present with an acute onset of apparent infectious origin with either an upper respiratory or gastrointestinal illness, fever, chills, tender lymphadenopathy, and malaise suggestive of a flu-like illness. In some cases, specific viral infections can be identified at the outset, particularly herpes viruses such as Epstein-Barr virus (EBV), human herpes virus-6 (HHV-6), and cytomegalovirus (CMV). Transfer factors (TF) with specific activity against these herpes viruses has been documented. With some studies suggesting that persistent viral activity may play a role in perpetuation of CFS symptoms, there appears to be a rationale for the use of TF in patients with CFS and recent reports have suggested that transfer factor may play a beneficial role in this disorder.
Structural nature and functions of transfer factors.
Ann N Y Acad Sci. 1993. Kirkpatrick CH.
Conrad D. Stephenson Laboratory for Research in Immunology, National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado 80206.
Transfer factors are molecules that "educate" recipients to express cell-mediated immunity. This effect is antigen-specific. The most consistent effects of transfer factors on the immune system are expression of delayed-type hypersensitivity and production of lymphokines such as macrophage migration inhibitory factor (MIF), which is probably identical to gamma-interferon in response to exposure to antigen. Transfer factors bind to antigens in an immunologically specific manner. This discovery has enabled us to isolate individual transfer factors from mixtures that contain several transfer factors. This reactivity probably explains the specificity of individual transfer factors, and it has provided a method for purification of individual transfer factors to apparent homogeneity. The purified materials are immunologically active and antigen-specific. They have molecular weights of approximately 5,000 Da and appear to be composed entirely of amino acids. Transfer factors appear to offer a novel means of molecular immunotherapy for certain patients with defective cell-mediated immunity.
Giancarlo Pizza, MD, of Bologna, Italy has
studied the use of transfer factor in the treatment of renal cell and
other kinds of cancer.
.... .... ..... ...
Universal Oral Vaccine: The Immune Milk Saga ? Part 2 by Anthony di Fabio
Scope of Protection
As already stated, appropriate scientific studies carried out in the early ?60s found promising success. They included rheumatoid arthritis, multiple sclerosis, rheumatic fever, and pollen allergies. Subsequent research has expanded this list considerably, including drying up some cancerous tumors.
According to Herbert Edwin Struss, PhD, one unpublished report showed ?spectacular? survival rates for small children from a poverty area in Mexico who were treated against colon bacteria with this method by cooperating Mexican physicians.
As a general principle, this method of preparing disease-specific colostrum will transfer adaptive immunity safely against any allergen or antigen ? any substance which, when introduced into the body, creates antibodies (such as allergenic pollens, house dust, animal hairs, or microorganism proteins). For allergy prevention, one can use a mixture of hair (cats, dogs, cattle), making a bovine cistern-injectable vaccine. Other allergens, like pollens, can also be introduced into the cow?s cistern resulting in colostrum that has the beneficial effects of developing resistance to the antigens that produce the allergies.
Experimental studies in the patents listed in the references attached include: "bacteria, viruses, proteins, animal tissue, plant tissue, spermatozoa, rickettsia, metazoan parasites, mycotic molds, fungi, pollens, dust and similar substances?exemplary antigens include: bacterial ? Salmonella pullorum, Salmonella typhi, Salmonella parathypi, Staphylococcus, aureus, a Streptoccous agalactiae, g Streptococcus agalactiae, Staphyloccus albus, Staphylococcus pyogenes, E. Coli, pneumococci, streptococci, and the like; viral ? influenza type A, fowl pox, turkey pox, herpes simplex and the like; protein ? egg albumin and the like; tissue ? blood and sperm."
In an experiment using immune milk conducted at Notre Dame University's Lobund Institute, Impro Products, Inc. substances reduced tooth decay in laboratory animals as much as 87%. (Although bacteria are usually blamed, the work of dentist Dr. Trevor Lyons clearly demonstrates a synergism between protozoans and bacteria, and the devastating effects of certain protozoans.5)
Trial mammals protected according to various immune milk patents were mice, cows, goats, chickens and pigs.
The immune milk method is also good for chickenpox, cold sores, genital herpes, Cryptocides sporidium, and for anti-inflammatory conditions, as it is heavy with complement (C3B) and anti-complement, substances that assist in the destruction of invasive organisms.
Other Sources than Immune Milk
Although not as economical or as easy to obtain as bovine or goat colostrum, the same disease-specific antibody and complement can also be obtained from other sources than colostrum. For example: (1) donors with high (cell-mediated) immunity to known antigens (cloning); (2) from human placentas, and (3) the spleen from immunized pigs or ducks, or even from humans who have good (cell-mediated) immunity to the relevant antigens.
Because these substances ? called ?transfer factors? ? are so cheap, widespread, and easy to use, various countries outside of the United States use it, including China, Czechoslovakia, Germany, Poland, and Hungary. In Japan, the only high-wage country where it is used, 40 Red Cross Centers provide transfer factor produced from pooled leukocytes (white blood cells) of normal healthy donors to 400 hospitals for use in a wide variety of conditions.
(Use of transfer factor does not cause hepatitis, but is effective against hepatitis, does not cause AIDS, and may be helpful in some of the diseases associated with AIDS.)
There are many particles that can transfer immunity. Subsequently confirmed by other scientists ? in reporting on membrane filtered (dialyzable) white blood cells (leukocytes) to obtain ?transfer-factors? ? they found that transfer of immunity had taken place in the following conditions:25-27
1. Familial T-lymphocyte dysfunction with severe recurrent infection (white cell dysfunction)
2. Herpes infection (viral)
3. Cytomegalovirus infection (viral)
4. Candidiasis (yeast/fungus)
5. Parasitic infection (e.g., pneumocystis carinae, cryptosporidiosis, etc.)
6. Mycobacterium tuberculosis infection refractory to antibiotics
7. Behcet's syndrome (skin condition/arthritis)
8. Lupus erythematosus
9. Pemphigus vegetans (skin disease)
10. Wiskott-Aldrich Syndrome (immune deficiency disease with decreased blood platelets and skin rash)
11. Florence Nightingale Disease (aka Chronic Fatigue Immune Dysfunction Syndrome)
12. Bone metastases after surgical removal of breast cancer
13. Bone metastases after surgical removal of kidney cancer
14. Guillian Barré (disturbance of two or more nerves, after viral or mycoplasma infection)
15. Amyotrophic lateral sclerosis (Lou Gehrig?s disease; one subset)
16. Retinitis Pigmentosa (inflamed retina: one subset, 50%; Dialyzable Leucocyte Extract-Transfer Factor ? filtered through a membrane ? does not reverse the disease but prevents additional visual loss)
Also reported by Fudenberg and Pizza,25-27 but not yet confirmed by others were:
1. Mycobacterium fortuitum infection (mycoplasma)
2. Mycobacterium avian infection (mycoplasma)
3. Alopecia totalis (hair loss over entire body)
4. Alzheimer's disease (one subset)
5. Autism (one subset, 70%)
6. Osteosarcoma (prevented metastases to lungs)
7. Epidermal dysplasia (multiple skin malignancies)
8. Certain food and chemical hypersensitivities
9. Burkitt's lymphoma, etc. (B-cell malignancy)
Reported by other than Fudenberg and Pizza25-27 were:
1. Lepromatous leprosy
2. Leishmaniasis (parasite affecting skin, nasal cavity and pharnyx)
3. Rat diabetes (Type I-immunologic) (trials in humans not yet reported, 1993)
4. Myasthenia gravis (great muscular weakness)
5. Subacute sclerosing panencephalitis (slow virus disease, affecting thinking and movement)
6. Atopic dermatitis (skin)
7. Bronchial asthma (lungs)
8. Recurrent otitis media (ears)
9. Varicella (virus)
10. Hepatitis B ? acute and chronic (virus)
11. Brucella (bacteria affecting humans and other mammals)
13. Nasopharyngeal carcinoma (cancer)
14. Stomach carcinoma (cancer)
15. Colon carcinoma (cancer)
16. Non-small cell lung carcinoma (cancer)
17. Spontaneous abortions
According to H. Hugh Fudenberg and Pizza,25 "The potential for bovine colostrum-transfer factor treatment of human diseases is fantastic since one can obtain so much more [transfer factor] extract at little cost."
Patents obtained by Stolle Milk Biologics International, as well as their present commercial partnership with the New Zealand Dairy Board also demonstrates that bovine intramuscular innoculations can result in a whey product containing the desired antibodies and complement.
So, clearly, there are many sources and paths to obtain the desired immunity factors that can be used sublingually or orally.
Early Clinical Trials
In the late sixties, Herbert Struss, PhD, working with the Borden Company of New York City, held a FDA IND (Investigational New Drug) authority for studying the use of bovine derived "Specific Serum Protein Capsules." Using 10 strains of Streptococcus, 2 strains of Staphyloccocus and 1 strain of Diplococcus in properly prepared cows, these lyophilized (freeze dried) serum proteins derived from colostrum were prepared in 250 mg capsules, and contained the gamma globulin fraction (protein in blood which helps resist disease) of the antibodies and immunity which enabled 70% of the Rheumatoid Arthritis victims to overcome the disease or receive marked benefit, once again demonstrating a close relationship between an infectious microorganism and Rheumatoid Arthritis.
Cyril M. Smith, MD, conducted a sample survey of 199 persons who used antibodies produced by cows in the treatment of arthritis symptoms. Smith reported that antibodies were successful in 56.8% of cases reported. This improvement occurred within 3 months. (The greatest improvement was noted between the second and fourth weeks. However, in some cases it required more than 6 weeks before a marked improvement was noticed.)
Twenty-three percent who found relief from symptoms while taking antibodies experienced an increase in pain prior to their improvement. This "increase in pain" was most likely the Herxheimer Effect as summarized by Dr. Paul K. Pybus.30 The great majority of the persons who experienced pain made marked improvement.
Herxheimer postulated that whenever an organism more complex than a simple bacteria was killed inside the human body, then flu-like symptoms ? the Herxheimer Effect ? occurred. This effect is also called "Lucio's Phenomena" in Leprosy treatment and "The Die-Off Effect" in candidiasis treatment. Some practitioners call it the ?Healing Effect.?
It?s extremely remarkable that such a high percentage of cure rates would occur using only a fraction (Staphyloccocus, Streptococcus, Diplococcus) of the suspected multitudes of microorganisms related to arthritis! Based on presumption of totally different organisms than those used to develop arthritis-specific antibodies and complement, both Roger Wyburn-Mason, MD, PhD (protozoas) and Thomas McPherson Brown, MD (mycoplasma) ? and their practitioner followers ? have achieved higher rates of cures, especially when proper diet and consideration for candidiasis and food allergies are also included in the treatment protocols.41
A brief summary of uses for immune milk follow:
Uses In Animals
? Bovine . . . extract-transfer factor made against the parasite coccidioides protects not only cows but also mice from an LD 90 dose (the dose necessary to kill 90% of a population). Bovine dialyzable (filtered) leucocyte (white cell) extract devoid of transfer factor has no protective effect;
? Bovine antigen-specific transfer factor is effective in treatment of human herpes infections;
? Bovine created for nematodes, Haemonchus contortus, Trichostrongylus axei infections is effective in sheep;
? Bovine . . . extract, from both lymph nodes and colostrum, against virus and parasitic diseases, have been used in dogs (canine parvovirus), pigs (swine transmissible pharynogeolaryngeotrache-itis), chickens (bursal disease, Newcastle's Disease, and other viral diseases);
? Coccidioides destroys $250 million per year of prize cattle in Texas. Lymph Node Leukocyte (white cell) Extract (with Transfer Factor) can protect cattle against this infection, and also prevents mastitis in cows, and death from infection in newborn calves;
? Horse dialyzable (filtered) leucocyte (white cell) extract is effective against rheumatism in horses.
? Bovine dialyzable (filtered) leucocyte (white cell) extract (with transfer factor) has been given repeatedly to humans without adverse reaction;
? Eradicated cryptosporidiosis in humans with diarrhea;
? Coccidioides derived transfer factor, eradicated diarrhea and eliminated ova and parasites from stools;
? Being used on 6,000,000 people in China to prevent acute and chronic infectious hepatitis;
? Many other conditions, as previously mentioned.
In most health food stores you?ll find a product called ?colostrum,? often touted for its ability to ?strengthen the immune system.?
It?s quite possible that a particular batch or manufacturer has produced colostrum that has beneficial effects in the strengthening of the immune system. It contains, after all, a multiplicity of important immune ?transfer factors? common to all mammals. And ? it?s even possible that a particular batch of colostrum will favorably affect the course of an allergic reaction to an allergen (pollen-based) or disease from an antigen (microorganism-based). But ? unless the manufacturer has injected into the cow?s cistern dead microorganisms specific to your disease (or allergens), the expectation of the cow?s naturally derived antibodies and complement matching those that you must have to counteract a particular dysfunction, is considerably less than the probability of one powerball ticket winning a $40,000,000 jackpot. Keep in mind that the cow will only have immunity factors related to the antigens to which it has been exposed ? and most modern dairies isolate their cows from most humans, thus preventing the nice, comfy farm ecological relationship once known to us.
Then, too, the odds increase the farther away one is from fresh, unpasteurized, whole colostrum! ? except for a handful of ?immune milk? companies who have applied modern technology in preserving most of the active ingredients in a dry powder or liquid form for use by all farm animals.
Many of these desirable immune factors can be purchased for protection of farm animals, but not for humans! Even so, the likelihood of getting the right product for you at the health food store, prepared and preserved in the right way, is so remote as to be inconsequential.
There are exceptions which we?ll mention shortly.
The 80 or so rheumatoid diseases, including rheumatoid arthritis, for example, are caused by many factors among which are nutritional, genetic predisposition, hormonal, mercury/nickel poisoning; herbicides and pesticides, toxic bowels, foci of infection and microorganism-based antigen/antibody immuno-complexes which are not easily swept out by a clogged up lymph system. Most standard colostrum preparations for rheumatoid arthritis are based on injections of staphyloccus and streptococcus antigens. We know that many organisms, such as mycoplasms, corneybacteria, klebsiella, candida and others can be the antigenic stimulation in the human that results in the symptoms of rheumatoid arthritis.41
On a hit or miss basis, then, if you happen to be a person suffering from a tissue sensitivity to staphylococcus and/or streptococcus, and you?re also suffering from an overwhelming invasion of staphylococcus and/or streptococcus, and you happen to buy colostrum containing antibodies and complement resulting from the effects of these two organisms as developed in the cow?s cistern, and the material you?ve purchased is still strong and active, then you might very well respond favorably to this particular colostrum.
But if your arthritis stems from a mycoplasm, corneybacteria, candida or klebsiella (among many other possible microorganisms), you?re just out of luck. ?It didn?t work!? you?d report to your friends, and the overall idea of using colostrum would be invalidated for you and your friends.
So, as you learn about the miracle of colostrum, don?t run out to the health food store and buy colostrum with the expectation of solving your health problems!
There is the need for specificity of allergen or antigen introduced in the right way, at the right time, with colostrum collected and preserved correctly, and administered properly, before this universal vaccine will work for you.
By the way, colostrum prepared and used properly has little to do with whether cow or goat milk is good or bad for you. Indeed, one of the allergies that the right colostrum can solve is that of allergic reactions to milk!
Next issue Part 3: How to Obtain Properly Prepared Colostrum: The Simplest Procedure
Anthony di Fabio
The Arthritis Trust
7376 Walker Road
Fairview, Tennessee 37062 USA
the following article was copied from the website < www.truthquest2.com >
A review from the Eclectic Medicine International (EMI) staff at http://www.holisticcancersolutions.com/
"Transfer Factor (TF) enables the recipient's immune system to deal with pathogens it couldn't successfully fight by itself.
TF is not simply a new medication; it is a whole new class of medicine, comparable in importance to antibiotics, with several significant differences. TF is a natural dietary supplement; antibiotics are not. TF works through the immune system as an "immune inducer"; antibiotics directly attack the microorganisms. TF is definitely not a drug; antibiotics are drugs. TF is just as effective against viruses and viral type cancers as against bacteria (although presently only anti-viral formulations are available); antibiotics are useless against viruses. Finally, bacteria are becoming resistant to antibiotics. By the very nature of the procedure, this cannot happen with TF for the simple reason that the immune system of the host animal organism, through which the preparations are obtained, always reacts to the exact strain of the pathogen introduced into its system.
Although TF is just in the process of emerging as a powerful modality, the concept is certainly not new. There is more than 50 years of intensive research backing it up, with hundreds, if not thousands of papers written about it.
TF is disease specific, which means that there are specific Transfer Factors targeting single diseases, like hepatitis, HIV, Epstein-Barr virus, etc.
It is interesting to review the reasons why TF didn't become a major therapeutic tool sooner. Adoptive transfer of antigen-specific cell-mediated immunity in humans was first demonstrated in 1949 by H.S. Lawrence. His reports created little interest in the immunologic community for several reasons. In 1955, the lymphocyte was mentioned for the first time as an immunologic organ. Before this, the lymphocyte had been studied in hematologic, rather than in immunologic terms. Although Lawrence clearly demonstrated that delayed cutaneous hypersensitivity (DH) responsiveness could also be transferred by soluble extracts of leukocytes from 20 ml of blood and termed the factor responsible for this phenomenon transfer factor (TF), at that time the significance of DH was unknown so TF received little attention. Skin testing, one of Lawrence's major research procedures, was used by allergists for whom immunologists had no respect at that time. Hence, Lawrence's observations did not excite the immunologic scientific community. At the same time, antibiotics reigned supreme, and highly respected immunologists made public statements about medical science's final victory over pathogens.
For the alternative/holistic physician, TF opens the door to a modality that deals effectively with a wide range of serious and "untreatable" conditions. The list of targeted diseases will grow monthly, as the company will release new, disease specific extracts.
What is the history of Transfer Factors (TF) ?
H.S. Lawrence discovered Transfer Factors in 1949. It was shown that specific cellular immunity could be transferred from one immunized individual donor, to a non-immunized recipient. Transfer Factor is present in the leukocytes, i.e. the white cells of the blood. Its small molecular weight (less than 10,000 DA) allows its extraction by dialysis, a procedure that eliminates all molecules larger than 10,000 DA. This method of preparation totally excludes not only the presence of viral particles, but also other large molecules, which could be immunogenic for the organism and create allergic reactions. Therefore, properly manufactured Transfer Factors are totally safe and it never produces adverse side effects.
Several studies in the last 30 years have confirmed the original observations and established that dialysates from immune Iymphocytes may transfer information to naive, i.e. non- immune Iymphocytes, not only in the test tube but also when administered to laboratory animals or to patients. This information concerns only cellmediated immunity but not humoral immunity (i.e. antibody production).
Cell-mediated immunity plays a key role in the control of infectious and autoimmune diseases, as well as cancer. Thus, Transfer Factors have been utilized for the treatment of diseases caused by viruses, parasites, fungi and
mycobacterium as well as autoimmune and malignant disorders. It is worth noting that Transfer Factor is extremely potent and it can be administered in very small amounts.
The mechanisms of action of Transfer Factors at the molecular level remain largely unknown. Each batch of Transfer Factor should be stringently tested for presence, activity, and potency.
Indeed, it is now established that the leukocyte dialysates contain several immuno-active components or Iymphokines, some being antigen-specific and others antigen-non-specific. It seems that they exert their specific or
non-specific effects on the T lymphocyte (Iymphocytes responsible for cell-mediated immunity) subpopulations.
Thus, for each sub-population there is a corresponding antigen-specific and probably also a non- specific factor. This is extremely important since, by exercising a balancing effect on the different sub-populations, transfer factor
achieves immunomodulation - i.e., a regulation of the immune reactions in order for the immune system to reach a healthy equilibrium. This is one of the reasons why no adverse effects owing to overdose has ever been observed
when the dialysates were administered to patients or laboratory animals.
Furthermore, by selecting the lymphocytes from which Transfer Factors are obtained, one can enrich the final preparation with molecules stimulating the corresponding lymphocyte subpopulation of the patient, e.g. suppressor,
cytotoxic or helper.
In this way, Transfer Factors may be used to decrease over-reactivity of the immune system as in the case of allergies and autoimmune disorders, as well as to increase or re-establish impaired immunity for combating existing infections, or transfer new immunological information to prevent new infections in exposed individuals. In other words, it could also be used for prophylaxis, i.e. as a vaccine addressing the cell-mediated immunity.
See Medline articles by authors including but not limited to:
H. Fudenberg, C. Kirkpatrick, G. Paddock, G. Pizza, D. Viza, G. Wilson
ANTIGEN SPECIFIC "TRANSFER FACTORS"
Five Decades of Research and Testing
Elevates the body's own immune system to specific antigens
Transfers distinct cell-mediated immunity to a deficient recipient
Remarkable treatment results have been achieved for viral, fungal and parasitic infections; including HIV and AIDS, Epstein~Barr virus, Herpes, Multiple Sclerosis, Alzheimer's disease, Autism, ALS (Lou Gerhig's Disease)
and Chronic Fatigue Syndrome
No known side effects: Non-toxic
A HISTORY OF HOPE - Long before many of today's immunodeficient patients were born, a significant discovery was made in 1949 by Dr. H.S. Lawrence. His discovery, now known worldwide as transfer factor (TF), spawned progressive, documented research which has had a fundamental impact on the effective treatments of patients in the 1990's.
Dr. Lawrence uncovered a vital component in the immunological maze -- the successful transfer of antigen-specific agents from a sensitized donor to an unsensitized recipient. In simpler terms, one person's immune response to a
certain disease could be precisely duplicated so that another person who had little or no immune response to the same agent could likewise fight off an infectious agent like streptococcus or Diphtheria. This "transfer factor"
was not thoroughly characterized, or for that matter understood at first, yet it was determined early on that TF was a small molecular weight ,
Other researchers, such as W. S. Jeter, came to similar conclusions about TF's capabilities in 1954. Healthy donor guinea pigs under certain circumstances, successfully transferred contact hypersensitivity to common substances, like poison ivy, to immune-deficient recipient animals.
While their contemporaries argued that prior to exposure to an antigen was likely in the recipients, Dr. Lawrence and Mr. Pappenheimer's further research brought consistent, heightened immune responses in human TF recipients. These findings were documented through extensive research done in 1960 by Rapaport et al.
Transfer factor acts as a "tailored" treatment by communicating the exact, immunological information from the donor to the recipient regarding a single, or as many as thousands of specific antigens.
In 1970, Dr. Hugh Fudenberg et al. began using TF treatment on patients suffering from Wiscott- Aldrich Syndrome. His scope later widened to include candidiasis, several viral-type cancers as well as fungal and parasitic
Research efforts subsided somewhat during the 1970's, largely due to the high price tag coupled with a focus on mostly rare viruses. Even so, immunologists remained very interested in TF's potential, and research slowly but surely moved forward.
Over the next decade, there were continuing revelations about the nature and targeted effectiveness of TF. For example, tests were conducted in 1981 by Dr. Kahn et al. Seventeen patients with Herpes were given TF injections at intervals of one week to 3 months, with noteworthy results. Sixteen of the seventeen patients involved in the study showed definite decreases in recurrence, with eight of those treated being completely free of the disease.
T-cell function improved significantly, and it was likewise noted that TF induced interferon (production) increase. A 29 year old woman with a long history of low immune resistance contracted both generalized herpes zoster and varicella pneumonia in 1985. Her condition was described as "desperate" due to respiratory failure and an overall degrading chest condition. She responded quickly after treatment with transfer factor from a healing herpes donor.
Once again, this case points to TF's ability to effectively target specific antigens.
The Epstein-Barr virus, in combination with a cytomegalo virus (CMV) infection, was treated in a four year old child who had suffered for two years with recurring fevers, rashes, abdominal pain and other nagging symptoms. He
was then given TF by mouth. Incredibly, his symptoms disappeared, and the child even developed a specific CMV immunity.
Additional case studies revealed transfer factor's effectiveness in treating candidiasis, crypeosporosis and Burkitt's Iymphoma.
TRANSFER FACTOR TODAY - Today, in the final decade of this century, transfer factor studies are consistently showing up worldwide. Several, including those from the National Academy of Science of the United States of America, have focused on the transmission relationship between an HIV type I infected mother and her unborn child. Generally, when the mother's viral load is decreased, so is the likelihood of HIV-I being transmitted to the baby. This was observed in 1995 from a group of thirty HIV- I pregnant women.
Dr. H. Hugh Fudenberg, M.D., has greatly broadened TF research and treatment efforts. To date, he is the only one to have successfully treated subsets of Alzheimer's Disease, Autism, Chronic Fatigue Syndrome and subsets of ALS (Lou Gerhig's Disease). Similar work by others points to Myasthenia Gravis and Multiple Sclerosis as having an immunological base which can be altered or reversed through large amounts of TF.
Infected patients who are tracked up to ten years show positive, residual TF effects. A large number of peer-reviewed scientific papers testified to these facts as well as TF's consistent track record of partially or completely reversing specific viral infections. Immunological researchers continue to explore new treatment applications for TF.
Transfer Factors clearly belong to the category of primary, frontline medications against chronic viral/bacterial infections, and against autoimmune diseases that are caused by such infections. As an anti-cancer agent, TF still has to prove its efficacy; this may happen in the near future.
Lengthy studies proved that TFs taken orally are quite effective. According to experts, oral introduction is just as effective as administration by injection."
Presently, to our best knowledge, the only laboratory in the United States that produces Transfer Factors for the public is Chisolm Biological Laboratories.
In case of a specific infection that doesn't respond to any treatment, it may help to inquire about a custom made TF extract for that specific pathogen. Chisolm Labs can be reached through the distributing company, AMERIDEN.
NAME OF TREATMENT: Antigen Specific Transfer Factor (True Transfer Factors/Immmunfactors #1-6)
MANUFACTURER: Chisolm Laboratories
AMERIDEN INTERNATIONAL P.O. Box 1870, Fallbrook, California 92088-1870
Tel: 888-405-3336 or 760-728-0747